In the claims:

Kindly amend the claims as follows.

1 (currently amended). A chimeric filovirus ~~GP~~ protein comprising GP1 or a portion thereof and GP2 or a portion thereof wherein said GP1 is chosen from a filovirus different than that of GP2.

2 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 1 wherein said GP1 or GP2 is from a filovirus chosen from the Genera consisting of Ebola and Marburg.

3 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 2 wherein said Ebola is chosen from the species Zaire, Sudan, Reston, and Cote d'Ivoire.

4 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 2 wherein said Marburg is chosen from the species Musoke, Ravn, and Popp.

5 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 1 wherein said GP1 is from Ebola and GP2 is from Marburg.

6 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 5 wherein said Ebola is strain Zaire and said Marburg is strain Musoke.

7 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 1 wherein said GP1 is from Marburg and GP2 is from Ebola.

8 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 7 wherein said Marburg is strain Musoke and said Ebola is strain Zaire.

9 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 1 wherein said GP1 is from Marburg strain Musoke and said GP2 is from Marburg strain Ravn.

10 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 1 wherein said GP1 is from Marburg strain Ravn and said GP2 is from Marburg strain Musoke.

11 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 6 wherein said chimeric ~~GP~~ protein is EBGP1/MBGP2 identified in SEQ ID NO:2 and conservative substitutions thereof, or an immunologically identifiable portion thereof.

12 (original). A DNA fragment encoding the chimeric protein of claim 11, said DNA identified in SEQ ID NO:1 and conservative substitutions thereof.

13 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 8 wherein said chimeric ~~GP~~ protein is MBGP1/EBGP2 identified in SEQ ID NO:4 and conservative substitutions thereof, or an immunologically identifiable portion thereof.

14 (original). A DNA fragment encoding the chimeric protein of claim 13, said DNA identified in SEQ ID NO:3.

15 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 9 wherein said chimeric ~~GP~~ protein is MUSGP1/RVNGP2 identified in SEQ ID NO:6 and conservative substitutions thereof, or an immunologically identifiable portion thereof.

16 (original). A DNA fragment encoding the chimeric protein of claim 15, said DNA identified in SEQ ID NO:5.

17 (currently amended). The chimeric filovirus ~~GP~~ protein according to claim 10 wherein said chimeric ~~GP~~ protein is RVNGP1/MUSGP2 identified in SEQ ID NO:8 and conservative substitutions thereof, or an immunologically identifiable portion thereof.

18 (original). A DNA fragment encoding the chimeric protein of claim 17, said DNA identified in SEQ ID NO:7.

19 (currently amended). A recombinant DNA construct comprising:

(i) a vector, and

(ii) a DNA fragment encoding a chimeric filovirus ~~GP~~ protein according to claim 1.

20 (original). The recombinant DNA construct according to claim 19 wherein said DNA fragment encodes any of the following chimeric proteins chosen from the group consisting of:

(i) Marburg Musoke GP1/Ebola Zaire GP2

(ii) Ebola Zaire GP1/Marbug Musoke GP2

(iii) Marburg Musoke GP1/Marburg Ravn GP2

(iv) Marburg Ravn GP1/Marburg Musoke GP2

21 (original). A recombinant DNA construct according to claim 20 wherein said vector is an expression vector.

22 (original). A recombinant DNA construct according to claim 20 wherein said vector is a prokaryotic vector.

23 (original). A recombinant DNA construct according to claim 20 wherein said vector is a eukaryotic vector.

24 (original). A recombinant DNA construct according to claim 20 wherein said vector is a VEE virus replicon vector.

25 (original). The recombinant DNA construct according to claim 24 wherein said construct is EBOV-MAY SP1 (aa1-501)/MBGV-MUS GP2 (aa436-681).

26 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-MUD GP1 (aa1-435)/EBOV-MAY GP2 (aa502-676).

27 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-RVN GP1 (aa1-435)/MBGV-MUS GP2 (aa436-681).

28 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-MUS GP1 (aa1-435)/MBGV-RVN GP2 (aa436-681).

29 (original). Self replicating RNA produced from the construct of any of claims 24-28.

30 (original). Infectious alphavirus particles produced from packaging the self replicating RNA of claim 29.

31 (original). A pharmaceutical composition comprising infectious alphavirus particles according to claim 30 in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.

32 (original). A host cell transformed with a recombinant DNA construct according to claim 19.

33 (original). A host cell according to claim 32 wherein said host cell is prokaryotic.

34 (original). A host cell according to claim 32 wherein said host cell is eukaryotic.

35 (currently amended). A method for producing chimeric filovirus ~~GP~~ proteins comprising culturing the cells according to claim 33 under conditions such that said DNA fragment is expressed and said chimeric protein is produced.

36 (currently amended). A method for producing chimeric filovirus ~~GP~~ proteins comprising culturing the cells according to claim 34 under conditions such that said DNA fragment is expressed and said chimeric protein is produced.

37 (currently amended). A vaccine for more than one filovirus comprising viral particles containing one or more replicon RNA encoding chimeric ~~GP~~ from one or more filovirus.

38 (currently amended). A vaccine against Ebola Zaire virus infection and Marburg Musoke virus infection comprising a chimeric ~~GP~~ protein according to claim 5.

39 (currently amended). A vaccine against Ebola Zaire virus infection and Marburg Musoke virus infection comprising a chimeric ~~GP~~ protein according to claim 7.

40 (currently amended). A vaccine against Marburg Musoke virus infection and Marburg Ravn virus infection comprising a chimeric ~~GP~~ protein according to claim 9.

41 (currently amended). A vaccine against Marburg Musoke virus infection and Marburg Ravn virus infection comprising a chimeric ~~GP~~ protein according to claim 10.

42 (original). A vaccine against Ebola Zaire virus infection and Marburg Musoke virus infection comprising infectious alphavirus particles produced from replicating RNA produced from the construct of claim 25.

43 (original). A vaccine against Ebola Zaire virus infection and Marburg Musoke virus infection comprising infectious alphavirus particles produced from replicating RNA produced from the construct of claim 26.

44 (original). A vaccine against Marburg Musoke virus infection and Marburg Ravn virus infection comprising infectious alphavirus particles produced from replicating RNA produced from the construct of claim 27.

45 (original). A vaccine against Marburg Musoke virus infection and Marburg Ravn virus infection comprising infectious alphavirus particles produced from replicating RNA produced from the construct of claim 28.

46 (original). A pharmaceutical composition comprising a chimeric peptide encoded by any of SEQ ID NO:1, 3, 5, or 7 in a pharmaceutically acceptable amount, in a pharmaceutically acceptable carrier and/or adjuvant.

47 (currently amended). A bivalent filovirus vaccine antigen comprising a chimeric ~~GP~~ protein comprising GP1 or a portion thereof from a first filovirus and GP2 or a portion thereof from a second filovirus, said antigen able to elicit an immune response to two filoviruses in a subject.

48 (currently amended). A multivalent filovirus vaccine antigen comprising a chimeric ~~GP~~ protein wherein GP1 is comprised of portions of GP1 from different filoviruses and GP2 ~~are~~ is comprised of portions of ~~GP1 and~~ GP2 chosen from different filoviruses, said antigen able to elicit an ~~immunt~~ immune response to more than two filoviruses in a subject.